Epic Sciences

In the News


Discover Magazine: Personalized cancer treatment, from just a blood sample.

Discover Magazine — Blood samples are an invaluable tool, but often they’re just the tip of the diagnostic iceberg, something that determines whether additional, more sensitive tests and scans might be necessary. But new technology being developed by San Diego-based Epic Sciences can determine whether a cancer patient is an appropriate candidate for a drug, and even whether the drug is losing its efficacy.


Xconomy: Epic Sciences compiling data on ultra-sensitive cancer diagnostic.

Xconomy — San Diego’s Epic Sciences said today it has signed an agreement with LabCorp (NYSE: LH) to help speed up European clinical trials that are using Epic’s technology to identify tumor cells in the blood.


New Assay could help predict onset of MI.

Healio — Use of a new fluid biopsy technique may help identify patients at high risk for MI, researchers reported.


U-T San Diego: Scripps invents way to spot spread of cancer.

San Diego, Union Tribune — The Scripps Research Institute has invented an experimental way to spot and analyze cells that break away from solid tumors, possibly giving doctors a faster and better way to treat a variety of cancers.


MedCity News: Cancer diagnostics firm that can enable personalized medicine raises $13M in Series B financing.

San Diego, MedCity News — San Diego-based biotech firm Epic Sciences announced Tuesday that the company has raised $13 million to pursue its molecular diagnostics technology that can better detect and monitor cancer as well as enable personalize cancer treatment.


Xconomist of the week: Peter Kuhn on detecting circulating tumor cells.

Xconomy — Worrying whether a solid tissue tumor might spread elsewhere in the body represents one of the biggest unknowns for many cancer patients, according to Peter Kuhn, an associate professor of cell biology at The Scripps Research Institute in San Diego.


Prostate Cancer Foundation: CTC technology detects presence of cancer and serves as a less invasive diagnostic tool.

Prostate Cancer Foundation — Through direct research funding and data sharing, the Prostate Cancer Foundation (PCF) funding has advanced the field of Circulating Tumor Cell (CTC) technology, which may soon deliver new gold standards for prostate cancer diagnostics and biomarkers.